Symbol="AUTL"
AssetType="Common Stock"
Name="Autolus Therapeutics Ltd"
Description="Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom."
CIK="1730463"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="FOREST HOUSE, 58 WOOD LANE, WHITE CITY, LONDON, GB"
FiscalYearEnd="September"
LatestQuarter="2023-06-30"
MarketCapitalization="569674000"
EBITDA="-159684000"
PERatio="None"
PEGRatio="None"
BookValue="1.32"
DividendPerShare="0"
DividendYield="0"
EPS="-1.24"
RevenuePerShareTTM="0.055"
ProfitMargin="0"
OperatingMarginTTM="-22.24"
ReturnOnAssetsTTM="-0.272"
ReturnOnEquityTTM="-0.699"
RevenueTTM="7486000"
GrossProfitTTM="-130860000"
DilutedEPSTTM="-1.24"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="6.78"
AnalystTargetPrice="7.98"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="62.1"
PriceToBookRatio="1.046"
EVToRevenue="6.47"
EVToEBITDA="-0.118"
Beta="1.516"
num_52WeekHigh="3.63"
num_52WeekLow="1.6"
num_50DayMovingAverage="2.792"
num_200DayMovingAverage="2.304"
SharesOutstanding="173681000"
DividendDate="None"
ExDividendDate="None"
symbol="AUTL"
open="3.30"
high="3.30"
low="3.12"
price="3.19"
volume="199733.00"
latest_trading_day="2023-08-25"
previous_close="3.28"
change="-0.09"
change_percent="-2.7439%"
aroon_positive_momentum_days="64"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="64"
Volume_recent_avg="603400"
Change_recent_avg="0.01"
Delta_recent_avg="0.18"
Variance_recent_avg="0.09"
Change_ratio_recent_avg="0.09"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="64"
Aroon_momentum_negative="36"
image_negative_thumbnail_id_1="111"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0065.jpeg"
image_negative_thumbnail_id_2="154"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0022.jpeg"
image_neutral_thumbnail_id_1="580"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0019.jpeg"
image_neutral_thumbnail_id_2="568"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0031.jpeg"
image_positive_thumbnail_id_1="697"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0011.jpeg"
image_positive_thumbnail_id_2="690"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0018.jpeg"
image_professor_thumbnail_id_1="1198"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0032.jpeg"
image_professor_thumbnail_id_2="1184"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
